MoonLake Immunotherapeutics MLTX
- sonelokimab — Hidradenitis Suppurativa Phase 3
- sonelokimab — Psoriatic Arthritis Phase 3
- sonelokimab — Palmoplantar Pustulosis Phase 2
- sonelokimab — Axial Spondyloarthritis Phase 2
IL-17A (4 companies · 11 programs)
Companies with an active program directed at IL-17A.
Oruka Therapeutics, Inc. ORKA
- ORKA-002 — Psoriasis Phase 2
- ORKA-002 — Psoriatic Arthritis
- ORKA-021 — Psoriasis
- ORKA-002 — Hidradenitis Suppurativa Phase 2
Zura Bio Ltd ZURA
- tibulizumab — Hidradenitis Suppurativa Phase 2
- tibulizumab — Diffuse Cutaneous Systemic Sclerosis Phase 2
Protagonist Therapeutics, Inc PTGX
- PN-881 — Plaque Psoriasis Phase 1